IZOZF - Izotropic Technology Founder Appointed Editor-In-Chief of Medical Physics Journal
(TheNewswire)
VANCOUVER, BC - TheNewswire – December 31, 2020 – Izotropic Corporation (“ Izotropic ” or the “ Company ”) (CSE: IZO ) (CNSX:IZO.CN) US (OTC: IZOZF )(FSE: 1R3 ) is pleased to highlight the appointment of Director andPrincipal Founder of Breast CT Technology, Dr. John M. Boone, as the Editor-In-Chief of the AmericanAssociation of Physicists in Medicine’s (AAPM) flagship medicaljournal ‘Medical Physics,’ effective January 1, 2021.
The Company congratulates Dr. Boone on thisappointment, as he continues to be recognized as a key thought leaderin the field of medical physics.
Dr. Boone has been active in journal editorial issuesfor over 3 decades and has previously served in leadership positionswith the AAPM, an organization of over 9000 scientists, includingChair of Science Council for 6 years, president (2015), and Chair ofthe Board (2016).
Dr. Boone’s appointment comes one year after he wasawarded the prestigious 2019 William D. Coolidge Award forthe recognition of his lifetime achievement in medical p hysics.
ON BEHALF OF THE BOARD
Robert Thast
Chief Executive Officer
For investor relations inquiries contact:
Dan Sammartino
Phone: 1-778-962-0234
Email: IR@izocorp.com
For general inquiries contact:
Izotropic Corporation
Phone: 1-833-IZOCORP
Email: info@izocorp.com
About Izotropic Corporation
Izotropic Corporation and its wholly owned U.S.operating subsidiary, Izotropic Imaging Corp. have
been established to commercialize the next generationof breast imaging technology for early diagnosis of breast cancer. TheIzotropic Breast CT Imaging System produces high resolution breastimages in 3D. A single 10 second breast CT scan acquires approximately500 images, without painful breast compression, providing radiologistswith fully 3D viewing of the scanned breast. Mammography scanningrequires compression of the breast between 2 imaging plates, resultingin 2D images.
The Company has the exclusive worldwide license fromthe University of California, Davis to commercialize the technologydeveloped by principal founder and Company director Dr. John M. Booneand researchers at UC Davis. The license includes all intellectualproperty, trade secrets, patents and patent-pending applications thatare the foundation of the Company’s breast CT imaging platform.
Approximately $20 million in research funding and over15 years of research and development have been invested in developingthis groundbreaking breast CT imaging technology. Research includes acurrent, ongoing $2.9M U.S. clinical trial at UC Davis Medical Center.
The Company founders believe that this technology willbe a disruptive entry to the market, overcoming many of the challengesfaced by existing breast imaging modalities.
Forward Looking Statements
This document may contain forward-looking statementsthat are based on the Company's expectations, estimates andprojections regarding its business and the economic environment inwhich it operates. These statements are not guarantees of futureperformance and involve risks and uncertainties that are difficult tocontrol or predict. Therefore, actual outcomes and results may differmaterially from those expressed in these forward-looking statements and readers should not place undue reliance onsuch statements. Statements speak only as of the date on which theyare made and the Company undertakes no obligation to update thempublicly to reflect new information or the occurrence of future eventsor circumstances, unless otherwise required to do so by law.
Copyright (c) 2020 TheNewswire - All rights reserved.